NCT05909098 is a Phase 1, PHASE2 clinical trial of autologous NK cell in NK Cell, sponsored by Xiangyang No.1 People's Hospital.

Who is sponsoring NCT05909098?

NCT05909098 is sponsored by Xiangyang No.1 People's Hospital.

What drugs are being tested in NCT05909098?

Interventions in NCT05909098: autologous NK cell.

What condition does NCT05909098 study?

NCT05909098 studies NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory.

Is NCT05909098 still recruiting?

NCT05909098 is currently not yet recruiting. Last updated 22 June 2023.

Last reviewed 2023-06-22 · How we verify

NCT05909098

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma

Not yet recruiting Phase 1, PHASE2 Last updated 22 June 2023

What this trial tests

Phase 1, PHASE2 trial testing autologous NK cell in NK Cell in 33 participants. Not yet recruiting.

Timeline

1 July 2023

Primary endpoint
30 December 2026

30 November 2028

Quick facts

Lead sponsor	Xiangyang No.1 People's Hospital
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 July 2023
Primary completion	30 December 2026
Estimated completion	30 November 2028
Sites	1 location across China

Drugs / interventions tested

autologous NK cell

Conditions studied

NK Cell — all drugs for NK Cell →
B-cell Lymphoma Recurrent — all drugs for B-cell Lymphoma Recurrent →
B-cell Lymphoma Refractory — all drugs for B-cell Lymphoma Refractory →

Sponsor

Xiangyang No.1 People's Hospital

Who can join

Adults 18 to 80, any sex, with NK Cell or B-cell Lymphoma Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was a single-arm trial of autologous NK cell adjuvant therapy for relapsed/refractory non-Hodgkin's B-cell lymphoma. The locations isXiangyang No.1 People's Hospital, Hubei University of Medicine. The population was relapsed/refractory non-Hodgkin's B-cell lymphoma. The sample size was 33. The intervention was R-GemOx regimen combined with autologous NK cells. The dose of autologous NK cells was body surface area x (2-4) x 109 cells. The course of treatment was once every 14 days. The primary outcome measure was ORR. The duration of assessment was for each treatment cycle, 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 3 years, and 5 years of treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for NK Cell

Currently open trials in the same condition.

NCT06835140 — CD123-CD16-NK Cells Immunotherapy for AML · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05909098 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiangyang No.1 People's Hospital
Last refreshed: 22 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05909098.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing